Argenica Therapeutics Ltd has released a press release.
Phase 1 Clinical Trial Progress Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
In the deck
Earlier from Argenica Therapeutics
- Safety Review Committee Approves Third Cohort Commencement
- Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial
- Safety Review Committee Approves Second Cohort
- No Serious Safety Issues Observed in First Cohort
- First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007
Later from Argenica Therapeutics
- SRC Approves Commencement Of Fourth And Final Cohort Dosing
- Successful Completion of Phase 1 Clinical Trial Dosing
- Argenica Awarded $1.2m CRC-P Grant for TBI Project
- Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
- Non-Dilutive Funding Received to Progress Alzheimers Studies
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics